1-5 of 5
Debashree Basudhar
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Cross-Cohort Correlative Analysis of Clinically High-Risk Patients (pts) Treated with Idecabtagene Vicleucel (ide-cel) in KarMMa-2: Association between Progression-Free Survival (PFS) and Tumor Burden and Immune Status at Apheresis

Debashree Basudhar, Dante Descalzi-Montoya, Hao Tang, Minshi Wang, Fan Wu, P. Leif Bergsagel, Xavier Leleu, Daniela Hosseyni, Maria Chaudhry, Nathan Martin, Ethan G. Thompson
Journal: Blood
Blood (2024) 144 (Supplement 1): 3382.
https://doi.org/10.1182/blood-2024-198740
Published: 2024
Journal Articles

Idecabtagene Vicleucel (Ide-cel) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) with an Inadequate Response to Front-Line Autologous Stem Cell Transplantation (ASCT): KarMMa-2 Cohort 2c Extended Follow-up

Barry Paul, Madhav V. Dhodapkar, Melissa Alsina, Jesús G. Berdeja, Shambavi Richard, Ravi Vij, Xavier Leleu, Daniel N. Egan, P. Leif Bergsagel, Ran Reshef, Saad Z. Usmani, Anna Truppel-Hartmann, Debashree Basudhar, Ethan G. Thompson, Fan Wu, Laurie Eliason, Soyun Park, Sinhan Tran, Maria Chaudhry, David S. Siegel, Krina K. Patel
Journal: Blood
Blood (2024) 144 (Supplement 1): 3388.
https://doi.org/10.1182/blood-2024-200829
Published: 2024
Journal Articles

Efficacy and Safety of Idecabtagene Vicleucel (ide-cel) in Patients with Clinical High-Risk Newly Diagnosed Multiple Myeloma (NDMM) with an Inadequate Response to Frontline Autologous Stem Cell Transplantation (ASCT): KarMMa-2 Cohort 2c Extended Follow-up

Madhav V. Dhodapkar, Melissa Alsina, Jesus G. Berdeja, Krina K. Patel, Shambavi Richard, Ravi Vij, Xavier Leleu, Daniel N. Egan, P. Leif Bergsagel, Ran Reshef, Saad Z Usmani, Anna Truppel-Hartmann, Debashree Basudhar, Ethan Thompson, Xirong Zheng, Laurie Eliason, Xiaobo Zhong, Chiara Greggio, Sinhan Tran, Maria Chaudhry, Marlene J. Carrasco-Alfonso, David S. Siegel
Journal: Blood
Blood (2023) 142 (Supplement 1): 2101.
https://doi.org/10.1182/blood-2023-173970
Published: 2023
Journal Articles

KarMMa-2 Cohort 2a: Efficacy and Safety of Idecabtagene Vicleucel in Clinical High-Risk Multiple Myeloma Patients with Early Relapse after Frontline Autologous Stem Cell Transplantation

Saad Usmani, Krina Patel, Parameswaran Hari, Jesus Berdeja, Melissa Alsina, Ravi Vij, Noopur Raje, Xavier Leleu, Madhav Dhodapkar, Ran Reshef, Anna Truppel-Hartmann, Debashree Basudhar, Ethan Thompson, Xirong Zheng, Revathi Ananthakrishnan, Chiara Greggio, Linda Favre-Kontula, Lars Sternas, Jesús San-Miguel
Journal: Blood
Blood (2022) 140 (Supplement 1): 875–877.
https://doi.org/10.1182/blood-2022-162469
Published: 2022
Journal Articles

KarMMa-2 Cohort 2c: Efficacy and Safety of Idecabtagene Vicleucel in Patients with Clinical High-Risk Multiple Myeloma Due to Inadequate Response to Frontline Autologous Stem Cell Transplantation

Madhav Dhodapkar, Melissa Alsina, Jesus Berdeja, Krina Patel, Ravi Vij, Xavier Leleu, Anna Truppel-Hartmann, Debashree Basudhar, Ethan Thompson, Xirong Zheng, Revathi Ananthakrishnan, Linda Favre-Kontula, Chiara Greggio, Lars Sternas, David Siegel
Journal: Blood
Blood (2022) 140 (Supplement 1): 7441–7443.
https://doi.org/10.1182/blood-2022-162615
Published: 2022